A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001) (Jade)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00561574
First received: November 19, 2007
Last updated: June 5, 2014
Last verified: June 2014
  Purpose

The current study is a 52-week safety study in elderly outpatients with chronic primary insomnia randomized to treatment with 1.5 mg or 3.0 mg of esmirtazapine (Org 50081, SCH 900265, MK-8265) to investigate the safety and tolerability of long-term treatment with esmirtazapine in elderly patients.


Condition Intervention Phase
Sleep Initiation and Maintenance Disorder; Elderly
Mental Disorder
Dyssomnias
Sleep Disorders
Sleep Disorder, Intrinsic
Drug: Esmirtazapine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Long-Term Safety Study of Org 50081 in Elderly Outpatients With Chronic Primary Insomnia Examining the Effects of 1.5 mg or 3.0 mg of Org 50081

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Number of Participants Who Experience at Least One Adverse Event (AE) [ Time Frame: Up to 53 weeks ] [ Designated as safety issue: Yes ]
    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to the study drug.

  • Number of Participants Who Discontinue Study Drug Due to an AE [ Time Frame: Up to 52 weeks ] [ Designated as safety issue: Yes ]
    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not related to the study drug.

  • Change From Baseline in Alertness at Awakening [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: Yes ]
    Alertness at awakening was assessed by participants using a 0-100 mm visual analog scale (VAS) in response to Weekly Sleep Diary question 6 "How did you feel upon awakening over the past 7 days?". Scores could range from 0=Tired to 100=Alert. Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using an observed cases (OC) approach.

  • Change From Baseline in Feeling Full of Energy [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: Yes ]
    Feeling full of energy was assessed by participants using a 0-100 mm visual analog scale (VAS) in response to Weekly Sleep Diary question 7 "How full of energy have you felt over the past 7 days?". Scores could range from 0=Terribly tired to 100=Full of energy. Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using an OC approach.

  • Change From Baseline in Ability to Work/Function [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: Yes ]
    Ability to work/function was assessed by participants using a 0-100 mm visual analog scale (VAS) in response to Weekly Sleep Diary question 8 "How were you able to work or function over the past 7 days?". Scores could range from 0=Not at all to 100=Very well. Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using an OC approach.

  • Change From Baseline in Total Nap Time [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: Yes ]
    Total nap time was assessed by participants in response to Weekly Sleep Diary question 9a "How much time per day did you nap, on average?". Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using an OC approach.


Secondary Outcome Measures:
  • Change From Baseline in Total Sleep Time (TST) [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    TST was defined as the time recorded by participants in response to Weekly Sleep Diary question 4 "During the past 7 nights, how much time did you actually spend sleeping, on average?". Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using a last observation carried forward (LOCF) approach.

  • Change From Baseline in Wake Time After Sleep Onset (WASO) [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    WASO was defined as the time recorded by participants in response to Weekly Sleep Diary question 4 "During the past 7 nights, how much time were you awake, on average, after falling asleep initially?" Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using a LOCF approach.

  • Change From Baseline in Sleep Latency (SL) [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    SL was defined as the time recorded by participants in response to Weekly Sleep Diary question 4 "During the past 7 nights, how long did it take you to fall asleep, on average?" Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using a LOCF approach.

  • Change From Baseline in Number of Awakenings (NAW) [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    NAW was defined as the time recorded by participants in response to Weekly Sleep Diary question 2a "During the past 7 nights, how many times did you wake up, on average?" Baseline was defined as the Day 1 assessment of Days -7 to 1 before any study drug was taken. Change from Baseline was calculated using a LOCF approach.


Enrollment: 259
Study Start Date: January 2008
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Esmirtazapine 1.5 mg
Participants receive esmirtazapine 1.5 mg tablets, one tablet administered orally once daily for up to 52 weeks
Drug: Esmirtazapine
One tablet daily
Experimental: Esmirtazapine 3.0 mg
Participants receive esmirtazapine 3.0 mg tablets, one tablet administered orally once daily for up to 52 weeks
Drug: Esmirtazapine
One tablet daily

Detailed Description:

Insomnia is a common complaint or disorder throughout the world. About one third of the population in the industrial countries reports difficulty initiating or maintaining sleep, resulting in a non-refreshing or non-restorative sleep. The majority of the insomniacs suffer chronically from their complaints.

The maleic acid salt of Org 4420, code name Org 50081 (esmirtazapine), was selected for development in the treatment of insomnia. The first clinical trial with esmirtazapine was a proof-of-concept trial with a four-way cross-over design. All 3 esmirtazapine dose groups showed a statistically significant positive effect on Total Sleep Time (TST) (objective and subjective) and Wake Time After Sleep Onset (WASO), as compared to placebo.

The current study is a 52-week safety study in elderly outpatients with chronic primary insomnia randomized to treatment with 1.5 mg or 3.0 mg of esmirtazapine to investigate the safety and tolerability of long-term treatment with esmirtazapine in elderly patients.

  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • are at least 65 years of age at screening;
  • sign written informed consent after the scope and nature of the investigation have been explained to them, before screening evaluations;
  • are able to speak, read and understand the language of the investigator, study staff (including raters) and the informed consent form, and possess the ability to respond to questions, follow instructions and complete questionnaires;
  • have demonstrated capability to independently complete the LogPad questionnaires in the week preceding randomization;
  • normal bedtime should be within the 21:00 - 01:00 hour range, with no more variation than 2 hours for 5 nights out of 7;
  • have a documented diagnosis of chronic primary insomnia, defined as fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV-TR) criteria for primary insomnia [DSM-IV-TR 307.42]) with a duration of >= 1 month;
  • fulfill the following criteria based on medical or sleep history. Each of these criteria should be present for at least 3 nights per week for at least one month;

    • TST <= 6.5 hours
    • WASO >= 60 minutes
    • Sleep Latency (SL) >= 30 minutes

Exclusion Criteria:

  • have other sleep disorders (DSM-IV-TR) e.g. rapid eye movement (REM) behavioral disorders, sleep related breathing disorders, periodic leg movement disorder, restless leg syndrome, narcolepsy, circadian sleep wake rhythm disorders, or any parasomnia;
  • have any significant medical or DSM-IV-TR psychiatric illness causing the sleep disturbances;
  • currently meet diagnostic criteria for DSM-IV-TR depression (Major Depressive Disorder [MDD]) or have been diagnosed and treated for MDD within the last 2 years;
  • have signs of dementia or other serious cognitive impairment, defined by a score of less than 26 on the Mini-Mental State Examination (MMSE);
  • have a history of bipolar disorder, a history of suicide attempt or a family history of suicide; A family history of suicide is defined as any history of suicide in the first and second degree family (parents, siblings, grandparents, or offspring), or a pattern of completed suicides (more than one) in the third degree family (aunts, uncles, nieces, and nephews);
  • are night workers or rotating shift workers;
  • are traveling, or have plans to travel, through more than three time zones during the trial, from the screening visit onwards;
  • have a significant, unstable medical illness e.g. acute or chronic pain, hepatic, renal, metabolic or cardiac disease;
  • have clinically relevant electrocardiogram (ECG) abnormalities at screening, as judged by the investigator;
  • have clinically relevant abnormal hematology or biochemistry values at screening, as judged by the investigator;
  • have DSM-IV-TR substance abuse or DSM-IV-TR addiction within the last year;
  • drink more than 2 alcoholic drinks in a day. One drink is approximately equal to: 12 oz or 360 mL of beer (regular or light), or 4 oz or 120 mL of red or white wine, or 2 oz or 60 mL of desert wine (e.g. port, sherry), or 12 oz or 360 mL of wine cooler (regular or light), or 1 oz or 30 mL or spirits (80 to 100 proof, e.g. whiskey, vodka);
  • had serious head injury or stroke within the past year, or a history of (non-febrile) seizures;
  • use psychotropic drugs affecting sleep within 2 weeks prior to randomization (fluoxetine: 5 weeks);
  • use concomitant medication affecting sleep (see Protocol Section 3.4, Concomitant medication);
  • smoke > 15 cigarettes per day and/or can not abstain from smoking during the night;
  • drink excessive amounts of caffeinated beverages (more than 500 mg caffeine per day);
  • have a positive urine drug screen at screening;
  • are routinely sleeping during daytime (napping) for more than 60 minutes per day, 3 times/ week;
  • have a body mass index (BMI) >= 36;
  • have a known hypersensitivity to mirtazapine or to any of the excipients;
  • participated in another clinical trial within the last 30 days prior to screening;
  • participated in another clinical trial using esmirtazapine (Org 50081) at any time.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00561574

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Director Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00561574     History of Changes
Other Study ID Numbers: P05697, 176005, 2007-003636-35
Study First Received: November 19, 2007
Results First Received: June 5, 2014
Last Updated: June 5, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Merck Sharp & Dohme Corp.:
elderly
randomized
double blind

Additional relevant MeSH terms:
Mental Disorders
Psychotic Disorders
Sleep Initiation and Maintenance Disorders
Sleep Disorders
Parasomnias
Dyssomnias
Sleep Disorders, Intrinsic
Schizophrenia and Disorders with Psychotic Features
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on July 22, 2014